Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01294228 · ClinicalTrials.gov registry record
Rapid Evaluation of Acute Kidney Injury With NGAL in Acutely Ill Patients in the ICU
A clinical trial, sponsored by Abbott RDx Cardiometabolic.
- Completed
- Registry status
- 1,001
- Enrollment target
NCT01294228: Completed study, sponsored by Abbott RDx Cardiometabolic.
NCT01294228 is a clinical trial that has completed, run by Abbott RDx Cardiometabolic. The registered enrollment target is 1,001 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01294228 has completed, sponsored by Abbott RDx Cardiometabolic.
- COMPLETED
- Registry status
- 1,001 participants
- Enrollment target
Study Summary
This is a multi-center, prospective, observational study of patients that are admitted to the intensive care unit (ICU). This study does not include any treatment or intervention and it is considered Nonsignificant Risk.
Primary Outcome
The efficacy of the Triage Neutraphil-Gelatinase Associated Lipocalin (NGAL) Test as an aid in the diagnosis of acute kidney injury (AKI) in an all-comers ICU setting. Final AKI diagnoses were established by an adjudication committee.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,001 participants |
| Start Date | 2011-03 |
| Est. Completion | 2014-12 |
What the finished NCT01294228 record still lists
NCT01294228 is an observational study that tracks outcomes without assigning an intervention. Its 1,001 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01294228 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01294228 about?
NCT01294228 is a clinical study titled "Rapid Evaluation of Acute Kidney Injury With NGAL in Acutely Ill Patients in the ICU". This is a multi-center, prospective, observational study of patients that are admitted to the intensive care unit (ICU). This study does not include any treatment or intervention and it is considered Nonsignificant Risk.
What is the current status of trial NCT01294228?
This trial is currently completed. The enrollment target is 1,001 participants. The study started on 2011-03. Estimated completion is 2014-12.
Who is sponsoring clinical trial NCT01294228?
This trial is sponsored by Abbott RDx Cardiometabolic, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06207864 · 1,001 participants · NA
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia